Table of Contents Chapter 1 Overview of Eye Drug 1.1 Definition of Eye Drug in This Report 1.2 Commercial Types of Eye Drug 1.2.1 Drops 1.2.2 Tablet & Capsule 1.3 Downstream Application of Eye Drug 1.3.1 Glaucoma 1.3.2 Retinal Disease 1.3.3 Bacterial Infection 1.3.4 Other 1.4 Development History of Eye Drug 1.5 Market Status and Trend of Eye Drug 2013-2023 1.5.1 United States Eye Drug Market Status and Trend 2013-2023 1.5.2 Regional Eye Drug Market Status and Trend 2013-2023 Chapter 2 United States Market Status and Forecast by Regions 2.1 Market Status of Eye Drug in United States 2013-2017 2.2 Consumption Market of Eye Drug in United States by Regions 2.2.1 Consumption Volume of Eye Drug in United States by Regions 2.2.2 Revenue of Eye Drug in United States by Regions 2.3 Market Analysis of Eye Drug in United States by Regions 2.3.1 Market Analysis of Eye Drug in New England 2013-2017 2.3.2 Market Analysis of Eye Drug in The Middle Atlantic 2013-2017 2.3.3 Market Analysis of Eye Drug in The Midwest 2013-2017 2.3.4 Market Analysis of Eye Drug in The West 2013-2017 2.3.5 Market Analysis of Eye Drug in The South 2013-2017 2.3.6 Market Analysis of Eye Drug in Southwest 2013-2017 2.4 Market Development Forecast of Eye Drug in United States 2018-2023 2.4.1 Market Development Forecast of Eye Drug in United States 2018-2023 2.4.2 Market Development Forecast of Eye Drug by Regions 2018-2023 Chapter 3 United States Market Status and Forecast by Types 3.1 Whole United States Market Status by Types 3.1.1 Consumption Volume of Eye Drug in United States by Types 3.1.2 Revenue of Eye Drug in United States by Types 3.2 United States Market Status by Types in Major Countries 3.2.1 Market Status by Types in New England 3.2.2 Market Status by Types in The Middle Atlantic 3.2.3 Market Status by Types in The Midwest 3.2.4 Market Status by Types in The West 3.2.5 Market Status by Types in The South 3.2.6 Market Status by Types in Southwest 3.3 Market Forecast of Eye Drug in United States by Types Chapter 4 United States Market Status and Forecast by Downstream Industry 4.1 Demand Volume of Eye Drug in United States by Downstream Industry 4.2 Demand Volume of Eye Drug by Downstream Industry in Major Countries 4.2.1 Demand Volume of Eye Drug by Downstream Industry in New England 4.2.2 Demand Volume of Eye Drug by Downstream Industry in The Middle Atlantic 4.2.3 Demand Volume of Eye Drug by Downstream Industry in The Midwest 4.2.4 Demand Volume of Eye Drug by Downstream Industry in The West 4.2.5 Demand Volume of Eye Drug by Downstream Industry in The South 4.2.6 Demand Volume of Eye Drug by Downstream Industry in Southwest 4.3 Market Forecast of Eye Drug in United States by Downstream Industry Chapter 5 Market Driving Factor Analysis of Eye Drug 5.1 United States Economy Situation and Trend Overview 5.2 Eye Drug Downstream Industry Situation and Trend Overview Chapter 6 Eye Drug Market Competition Status by Major Players in United States 6.1 Sales Volume of Eye Drug in United States by Major Players 6.2 Revenue of Eye Drug in United States by Major Players 6.3 Basic Information of Eye Drug by Major Players 6.3.1 Headquarters Location and Established Time of Eye Drug Major Players 6.3.2 Employees and Revenue Level of Eye Drug Major Players 6.4 Market Competition News and Trend 6.4.1 Merger, Consolidation or Acquisition News 6.4.2 Investment or Disinvestment News 6.4.3 New Product Development and Launch Chapter 7 Eye Drug Major Manufacturers Introduction and Market Data 7.1 Pfizer 7.1.1 Company profile 7.1.2 Representative Eye Drug Product 7.1.3 Eye Drug Sales, Revenue, Price and Gross Margin of Pfizer 7.2 Novartis 7.2.1 Company profile 7.2.2 Representative Eye Drug Product 7.2.3 Eye Drug Sales, Revenue, Price and Gross Margin of Novartis 7.3 bausch Lomb 7.3.1 Company profile 7.3.2 Representative Eye Drug Product 7.3.3 Eye Drug Sales, Revenue, Price and Gross Margin of bausch Lomb 7.4 Laboratoire Riva 7.4.1 Company profile 7.4.2 Representative Eye Drug Product 7.4.3 Eye Drug Sales, Revenue, Price and Gross Margin of Laboratoire Riva 7.5 Jamp Pharma 7.5.1 Company profile 7.5.2 Representative Eye Drug Product 7.5.3 Eye Drug Sales, Revenue, Price and Gross Margin of Jamp Pharma 7.6 Fresenius 7.6.1 Company profile 7.6.2 Representative Eye Drug Product 7.6.3 Eye Drug Sales, Revenue, Price and Gross Margin of Fresenius 7.7 Teva Pharmaceutical 7.7.1 Company profile 7.7.2 Representative Eye Drug Product 7.7.3 Eye Drug Sales, Revenue, Price and Gross Margin of Teva Pharmaceutical 7.8 SANDOZ 7.8.1 Company profile 7.8.2 Representative Eye Drug Product 7.8.3 Eye Drug Sales, Revenue, Price and Gross Margin of SANDOZ 7.9 Greenstone 7.9.1 Company profile 7.9.2 Representative Eye Drug Product 7.9.3 Eye Drug Sales, Revenue, Price and Gross Margin of Greenstone 7.10 Mylan 7.10.1 Company profile 7.10.2 Representative Eye Drug Product 7.10.3 Eye Drug Sales, Revenue, Price and Gross Margin of Mylan 7.11 GE Medical 7.11.1 Company profile 7.11.2 Representative Eye Drug Product 7.11.3 Eye Drug Sales, Revenue, Price and Gross Margin of GE Medical 7.12 Mint Pharmaceuticals 7.12.1 Company profile 7.12.2 Representative Eye Drug Product 7.12.3 Eye Drug Sales, Revenue, Price and Gross Margin of Mint Pharmaceuticals 7.13 Laboratoires Thea 7.13.1 Company profile 7.13.2 Representative Eye Drug Product 7.13.3 Eye Drug Sales, Revenue, Price and Gross Margin of Laboratoires Thea 7.14 Taj Pharmaceuticals 7.14.1 Company profile 7.14.2 Representative Eye Drug Product 7.14.3 Eye Drug Sales, Revenue, Price and Gross Margin of Taj Pharmaceuticals 7.15 Actavis 7.15.1 Company profile 7.15.2 Representative Eye Drug Product 7.15.3 Eye Drug Sales, Revenue, Price and Gross Margin of Actavis 7.16 APOTEX 7.17 Sun Pharma Chapter 8 Upstream and Downstream Market Analysis of Eye Drug 8.1 Industry Chain of Eye Drug 8.2 Upstream Market and Representative Companies Analysis 8.3 Downstream Market and Representative Companies Analysis Chapter 9 Cost and Gross Margin Analysis of Eye Drug 9.1 Cost Structure Analysis of Eye Drug 9.2 Raw Materials Cost Analysis of Eye Drug 9.3 Labor Cost Analysis of Eye Drug 9.4 Manufacturing Expenses Analysis of Eye Drug Chapter 10 Marketing Status Analysis of Eye Drug 10.1 Marketing Channel 10.1.1 Direct Marketing 10.1.2 Indirect Marketing 10.1.3 Marketing Channel Development Trend 10.2 Market Positioning 10.2.1 Pricing Strategy 10.2.2 Brand Strategy 10.2.3 Target Client 10.3 Distributors/Traders List Chapter 11 Report Conclusion Chapter 12 Research Methodology and Reference 12.1 Methodology/Research Approach 12.1.1 Research Programs/Design 12.1.2 Market Size Estimation 12.1.3 Market Breakdown and Data Triangulation 12.2 Data Source 12.2.1 Secondary Sources 12.2.2 Primary Sources 12.3 Reference

List of Tables Table Advantage and Disadvantage of Drops Table Advantage and Disadvantage of Tablet & Capsule Table Consumption Volume of Eye Drug in United States by Regions 2013-2017 Table Revenue of Eye Drug in United States by Regions 2013-2017 Table Consumption Volume of Eye Drug in United States by Regions 2018-2023 Table Revenue of Eye Drug in United States by Regions 2018-2023 Table Consumption Volume of Eye Drug in United States by Types 2013-2017 Table Revenue of Eye Drug in United States by Types 2013-2017 Table Consumption Volume of Eye Drug by Types in New England 2013-2017 Table Consumption Volume of Eye Drug by Types in The Middle Atlantic 2013-2017 Table Consumption Volume of Eye Drug by Types in The Midwest 2013-2017 Table Consumption Volume of Eye Drug by Types in The West 2013-2017 Table Consumption Volume of Eye Drug by Types in The South 2013-2017 Table Consumption Volume of Eye Drug by Types in Southwest 2013-2017 Table Consumption Volume Forecast of Eye Drug in United States by Types 2018-2023 Table Revenue Forecast of Eye Drug in United States by Types 2018-2023 Table Demand Volume of Eye Drug in United States by Downstream Industry 2013-2017 Table Demand Volume of Eye Drug by Downstream Industry in New England 2013-2017 Table Demand Volume of Eye Drug by Downstream Industry in The Middle Atlantic 2013-2017 Table Demand Volume of Eye Drug by Downstream Industry in The Midwest 2013-2017 Table Demand Volume of Eye Drug by Downstream Industry in The West 2013-2017 Table Demand Volume of Eye Drug by Downstream Industry in The South 2013-2017 Table Demand Volume of Eye Drug by Downstream Industry in Southwest 2013-2017 Table Demand Volume Forecast of Eye Drug in United States by Downstream Industry 2018-2023 Table Sales Volume of Eye Drug in United States by Major Players 2013-2017 Table Revenue of Eye Drug in United States by Major Players 2013-2017 Table Headquarters Location and Established Time of Eye Drug Major Players Table Employees and Revenue Level of Eye Drug Major Players Table Representative Eye Drug Product One of Pfizer Table Representative Eye Drug Product Two of Pfizer Table Eye Drug Sales, Revenue, Price and Gross Margin of Pfizer 2013-2017 Table Representative Eye Drug Product One of Novartis Table Representative Eye Drug Product Two of Novartis Table Eye Drug Sales, Revenue, Price and Gross Margin of Novartis 2013-2017 Table Representative Eye Drug Product One of bausch Lomb Table Representative Eye Drug Product Two of bausch Lomb Table Eye Drug Sales, Revenue, Price and Gross Margin of bausch Lomb 2013-2017 Table Representative Eye Drug Product One of Laboratoire Riva Table Representative Eye Drug Product Two of Laboratoire Riva Table Eye Drug Sales, Revenue, Price and Gross Margin of Laboratoire Riva 2013-2017 Table Representative Eye Drug Product One of Jamp Pharma Table Representative Eye Drug Product Two of Jamp Pharma Table Eye Drug Sales, Revenue, Price and Gross Margin of Jamp Pharma 2013-2017 Table Representative Eye Drug Product One of Fresenius Table Representative Eye Drug Product Two of Fresenius Table Eye Drug Sales, Revenue, Price and Gross Margin of Fresenius 2013-2017 Table Representative Eye Drug Product One of Teva Pharmaceutical Table Representative Eye Drug Product Two of Teva Pharmaceutical Table Eye Drug Sales, Revenue, Price and Gross Margin of Teva Pharmaceutical 2013-2017 Table Representative Eye Drug Product One of SANDOZ Table Representative Eye Drug Product Two of SANDOZ Table Eye Drug Sales, Revenue, Price and Gross Margin of SANDOZ 2013-2017 Table Representative Eye Drug Product One of Greenstone Table Representative Eye Drug Product Two of Greenstone Table Eye Drug Sales, Revenue, Price and Gross Margin of Greenstone 2013-2017 Table Representative Eye Drug Product One of Mylan Table Representative Eye Drug Product Two of Mylan Table Eye Drug Sales, Revenue, Price and Gross Margin of Mylan 2013-2017 Table Representative Eye Drug Product One of GE Medical Table Representative Eye Drug Product Two of GE Medical Table Eye Drug Sales, Revenue, Price and Gross Margin of GE Medical 2013-2017 Table Representative Eye Drug Product One of Mint Pharmaceuticals Table Representative Eye Drug Product Two of Mint Pharmaceuticals Table Eye Drug Sales, Revenue, Price and Gross Margin of Mint Pharmaceuticals 2013-2017 Table Representative Eye Drug Product One of Laboratoires Thea Table Representative Eye Drug Product Two of Laboratoires Thea Table Eye Drug Sales, Revenue, Price and Gross Margin of Laboratoires Thea 2013-2017 Table Representative Eye Drug Product One of Taj Pharmaceuticals Table Representative Eye Drug Product Two of Taj Pharmaceuticals Table Eye Drug Sales, Revenue, Price and Gross Margin of Taj Pharmaceuticals 2013-2017 Table Representative Eye Drug Product One of Actavis Table Representative Eye Drug Product Two of Actavis Table Eye Drug Sales, Revenue, Price and Gross Margin of Actavis 2013-2017